Gut microbiota and nonalcoholic fatty liver disease

Boyeon Kim¹, Bukyung Kim²

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea
²Division of Endocrinology and Metabolism, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea

The gut microbiota has been reported to exert a significant influence on various physiological responses of hosts. Extensive evidence has recently emerged linking metabolic and cardiovascular disorders to the gut microbiota. Nonalcoholic fatty liver disease (NAFLD) is the most common underlying metabolic disorder, and its prevalence is increasing worldwide. In this study, we aim to review the relationship between the gut microbiota and NAFLD, and explore the potential of the gut microbiota as a novel target for NAFLD treatment.

Keywords: Gut microbiome; Gut microbiota; Non-alcoholic fatty liver disease; Steatohepatitis

Introduction

The gut microbiota in adults is known to comprise between 10 and 100 trillion microorganisms, a quantity that is more than 10-fold the number of human cells [1]. Moreover, the collective genomes of the gut microbiota are 100 to 150 times greater than that of the human genome [2]. Several metagenomic studies have suggested a correlation between the quantity or diversity of genes in the gut microbiota and the health of the host [3-5]. The gut microbiota has evolved alongside human evolution and has been found to significantly influence various physiological responses of the host. Notably, recent studies have demonstrated that alterations in the gut microbial composition are associated with various metabolic diseases, including obesity [6], nonalcoholic fatty liver disease (NAFLD) [7], type 2 diabetes [8], and cardiovascular disease [9-11].

More than one-third of the global population is affected by NAFLD, and the prevalence of this condition has significantly increased [12]. NAFLD induces insulin resistance and generates numerous inflammatory cytokines, bile acid, and cholesterol. Collectively, these factors can lead to type 2 diabetes, and conversely, type 2 diabetes can exacerbate NAFLD [13-17]. Furthermore, NAFLD is a significant contributor to the onset of cardiovascular diseases [18,19]. NAFLD can progress to liver inflammation and hepatocyte damage, resulting in nonalcoholic steatohepatitis (NASH). In some patients, NASH can cause slow, progressive, and severe liver damage, including fibrosis and ultimately, liver cirrhosis (LC). Therefore, NAFLD acts as a fundamental underlying condition contributing to various metabolic disorders.

In this article, we aim to review the relationship between the gut microbiota and NAFLD, as established by various...
studies to date. We also explore the potential of the gut microbiota as a novel therapeutic target for NAFLD in the future.

**Gut microbiota and NAFLD: pathogenic mechanisms**

Dysbiosis of the gut microbiota is recognized as a cause of NAFLD and NASH. Various environmental factors influence this dysbiosis. Notably, a diet high in fat and fructose, extensive exposure to medications such as antibiotics and proton pump inhibitors, and various food preservatives are identified as significant environmental contributors to gut microbiota dysbiosis [20-24]. Fructose, which is a monosaccharide naturally found in fruits and honey, has been demonstrated to play a substantial role in the pathogenesis of NAFLD and NASH in both preclinical and clinical studies [25-28], and it is known to induce gut microbiota dysbiosis [29,30]. In addition to its impact on gut microbiota, fructose also has direct, detrimental effects on the liver. Its unique metabolic pathway leads to ATP depletion, uric acid generation, mitochondrial dysfunction, de novo lipogenesis, and the inhibition of beta-fatty oxidation [31-35].

Small internal bacterial overgrowth and gut leakiness play a key role in the occurrence and progression of NAFLD (Fig. 1). Small internal bacterial overgrowth is commonly triggered by an imbalance in gut microbiota [36]. This imbalance leads to an increase in various microbial components and metabolites, including ethanol, lipopolysaccharide, trimethylamine, short-chain fatty acids, and microbial DNA. These elements, along with intestinal mucosal lesions, contribute to increased gut permeability [37,38]. Gut leakiness can also result from dysfunction in the structures of the intestinal barrier. Proteins in the tight junctions serve as crucial mucosal barriers that prevent bacterial translocation. When these proteins are damaged, the translocation of microbial metabolic products, such as lipopolysaccharide, into the bloodstream is increased. This process induces a state of endotoxemia, triggering inflammation in the liver [37,38]. The endotoxemia caused by increased intestinal permeability and the subsequent translocation to the liver are critical factors in the development of NAFLD (Fig. 1).

The gut-liver axis refers to the communication between the gut and the liver. This communication is bidirectional and occurs through the biliary tract, portal vein, and systemic circulation (Fig 1). Endotoxins that reach the liver via the portal vein interact with receptors such as Toll-like receptors 4 or 9 (TLR4 or TLR9). TLR4 is found on the cell membranes of hepatocytes and immune cells, specifically Kupffer cells. TLR4 facilitates the activation of molecules such as NF-κB, which in turn activate inflammatory cytokines [39,40]. The biliary tract plays a pivotal role in enabling bidirectional communication between the liver and
Numerous studies have targeted the gut microbiota for interventions. Gut microbiota and NAFLD: therapeutic combination of multiple species of probiotics. Mophiles, such as Lactobacillus bulgaricus and Lactobacillus casei, have been used to improve the condition of NAFLD, and the results have shown promise in reducing intrahepatic fat. However, interventional clinical studies to determine whether these specific species can cause NAFLD, in order to establish causality, are not feasible due to observations from several studies that these species change following bariatric metabolic surgery. Certain specific species have been utilized in the treatment of NAFLD, and the results have shown promise in improving the condition. The most used probiotics belong to the Lactobacillus genus, as follows: Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus bulgaricus, and Lactobacillus acidophilus. Others include Bifidobacteria and Streptococcus thermophiles. Numerous studies have recently explored the combination of multiple species of probiotics.

Keystone species of gut microbiota

Patients with NAFLD have been found to exhibit alterations in their gut microbiota compared to healthy individuals. Notably, the gut microbiota signatures associated with NAFLD include an increase in the Proteobacteria phylum, the Enterobacteriaceae family, and the Escherichia, Bacteroides, Dorea, and Peptoniphilus genera. Conversely, there is a decrease in the Rikenellaceae and Ruminococcaceae families, and the Faecalibacterium, Coprococcus, Anaerosporobacter, and Eubacterium genera. However, interventional clinical studies to determine whether these specific species are involved in the progression of NAFLD, in order to establish causality, are not feasible due to observations from several studies that these species change following bariatric metabolic surgery.

Certain specific species have been utilized in the treatment of NAFLD, and the results have shown promise in improving the condition. The most used probiotics belong to the Lactobacillus genus, as follows: Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus bulgaricus, and Lactobacillus acidophilus. Others include Bifidobacteria and Streptococcus thermophiles. Numerous studies have recently explored the combination of multiple species of probiotics.

Gut microbiota and NAFLD: therapeutic interventions

Numerous studies have targeted the gut microbiota for therapeutic and preventative interventions. These interventions encompass probiotics, prebiotics, synbiotic supplements, and fecal microbiota transplantation (FMT). In the context of NAFLD treatment, research has been conducted to alter the gut microbiota composition and reestablish balance through the administration of probiotics, prebiotics, and synbiotic supplements. Probiotics are specific species that could offer beneficial effects. Prebiotics have recently been defined as indigestible dietary components that selectively stimulate the growth and activity of beneficial gut bacteria. This definition has been broadened to include not only indigestible carbohydrates such as fructooligosaccharides, galactooligosaccharides, and trans-galactooligosaccharides, but also other substances like polysaccharides and polyphenols that can modulate the gut microbiota. Synbiotics are defined as a mixture of probiotics and prebiotics.

Animal studies have shown that probiotics can slow the progression of NAFLD. Furthermore, a meta-analysis of clinical studies, in which patients with NAFLD were treated with probiotics, revealed significant reductions in alanine aminotransferase, aspartate aminotransferase, and total cholesterol within the probiotics group. Although the number of patients included in these studies is limited, making it challenging to evaluate any actual changes in the composition of the intestinal microflora posttreatment, probiotics, prebiotics, and synbiotic supplements are associated with minimal side effects. Therefore, the results of future research are eagerly anticipated. A randomized controlled study of FMT, where fecal bacteria from healthy individuals are transplanted into NAFLD patients, has also been recently published. The group that underwent FMT showed improved intestinal permeability. However, there was no observed difference in insulin resistance or intrahepatic fat. In the same study, while an increase in bacterial diversity was noted, there were no definitive changes in the composition of the microbiota. This lack of change in microbiota composition may be due to the administration of FMT into the duodenum. Stool specimen analysis may not accurately reflect changes in the microbiome of the small intestine or the proximal colon. Conversely, another clinical trial where FMT was administered via colonoscopy demonstrated changes in both the composition of the microbiota and fatty liver post-FMT. Therefore, further research is needed to explore the therapeutic
effects of FMT in patients with NAFLD.

Another promising area for therapeutic intervention lies in factors associated with bile acid metabolism. Bile acids serve to prevent intestinal bacterial overgrowth, both directly and indirectly. Obeticholic acid (OCA), a potent activator of the farnesoid X receptor, has been shown to improve hepatic steatosis and fibrosis in animal studies [70]. Furthermore, OCA has been found to reduce bacterial translocation and improve gut microbiota dysbiosis in rats with LC [71]. A phase 3 clinical trial with OCA demonstrated a protective effect against fibrosis, as confirmed by biopsy [72]. However, despite these promising results, numerous patients have reported unusual observations, such as dermatological manifestations, during clinical trials. Consequently, the applicability of OCA to patients remains unconfirmed and is a subject of ongoing debate. Fibroblast growth factor 19 is a gut hormone that plays a major role in regulating bile acid metabolism [73,74]. The fibroblast growth factor 19 analog NGM282, which regulates bile acid synthesis and glucose homeostasis, has been shown to reduce hepatic steatosis in patients with NASH. A phase 2 study of NAFLD with NGM282, published in 2018, revealed that the treatment group experienced significant reductions in intrahepatic fat, fibrosis-related markers, and intrahepatic fat content within 12 weeks [75]. Regarding drug side effects, only mild symptoms such as digestive discomfort and pain at the injection site have been reported [75]. Further research results on the use of NGM282 to treat NAFLD and NASH are expected in the future.

Conclusion

Gut microbiota dysbiosis resulting from various environmental factors causes NAFLD. There have been attempts to identify treatment targets for NAFLD through studies on the mechanisms through which gut dysbiosis causes NAFLD. Moreover, numerous studies have shown improvements in NAFLD by directly restoring the composition of intestinal microbiota through probiotics, prebiotics, synbiotics, and FMT. In the future, studies exploring how the gut microbiome could be targeted for the treatment of NAFLD are expected.


60. Arellano–Garcia L, Portillo MP, Martinez JA, Milton–Laskibar I. Usefulness of probiotics in the management of NAFLD: evi-


